Document Detail


Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders.
MedLine Citation:
PMID:  20415778     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Public health can be protected most effectively through vaccination programmes. However, while presently available vaccination techniques protects the individual by provoking immune responses against exogenous antigens (ags), such as those associated with certain bacteria and viruses, they cannot protect against or treat mishaps caused by endogenous ag. Recently, Barabas and colleagues have developed a new vaccination method, called modified vaccination technique (MVT), which allows the presentation of disease causing agents in such a way as to initiate and maintain desired immune response outcomes even in the context of mishaps associated with endogenous ag. For example, in an experimental autoimmune kidney disease, the MVT downregulated/terminated pathogenic immune responses that were causing morphological and functional changes of the kidney. The MVT promises, with appropriate case-specific modifications, both preventative and curative applications for ailments, such as endogenous ag initiated mishaps (i.e. autoimmune diseases and cancer) and diseases caused by chronic infection, that are presently only treatable with drugs. To achieve specific immune responses, purified components of the vaccine (ag and antibodies) must be produced and assembled into immune complexes having the potential of inducing predetermined corrective immune response outcomes.
Authors:
Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Richard M Graeff; Rene Lafreniere; Donald M Weir
Related Documents :
11370768 - Vaccine against helicobacter pylori?
2687948 - Rna virus evolution and the control of viral disease.
9393788 - Therapeutic intragastric vaccination against helicobacter pylori in mice eradicates an ...
11064318 - Protective antigens and mechanisms of anti-candida immunity.
19196198 - Social and behavioral science in hiv vaccine trials: a gap assessment of the literature.
11069388 - Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Scandinavian journal of immunology     Volume:  71     ISSN:  1365-3083     ISO Abbreviation:  Scand. J. Immunol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-04-26     Completed Date:  2010-06-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0323767     Medline TA:  Scand J Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  125-33     Citation Subset:  IM    
Affiliation:
Department of Surgery, University of Calgary, Calgary, AB, Canada. barabas@ucalgary.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigen Presentation / immunology
Antigen-Antibody Complex / immunology
Antigens, Neoplasm / immunology
Autoantibodies / immunology
Autoantigens / immunology*
Autoimmune Diseases / immunology,  prevention & control*,  therapy
Cancer Vaccines / therapeutic use
Humans
Immunoglobulin G / immunology
Immunoglobulin M / immunology
Kidney Diseases / immunology,  prevention & control*,  therapy
Rats
Vaccination / methods*
Chemical
Reg. No./Substance:
0/Antigen-Antibody Complex; 0/Antigens, Neoplasm; 0/Autoantibodies; 0/Autoantigens; 0/Cancer Vaccines; 0/Immunoglobulin G; 0/Immunoglobulin M

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differences in exposure assignment between conception and delivery: the impact of maternal mobility.
Next Document:  IL-23 in the pathogenesis of rheumatoid arthritis.